---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-040809"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:38:47.822937+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics Q1 2025 net loss $11.9M; TARA-002 100% CR in BCG-Unresponsive cohort

## Summary
- Cash, cash equivalents and investments total $157.5M as of Mar 31, 2025; expected to fund operations into 2027.
- TARA-002 in BCG-Unresponsive NMIBC: 100% complete response (CR) at any time (5/5), 67% CR at 12 months (2/3) as of Apr 16, 2025.
- Interim results from ~25 six-month evaluable BCG-Unresponsive patients expected by end of 2025; THRIVE-3 trial of IV Choline Chloride to start Q3 2025.
- Appointed Leonardo Viana Nicacio, M.D., as CMO and Shane Williams, Ph.D., as VP, Head of HR/Chief People Officer in April 2025.
- Net loss $11.9M ($0.29/sh) vs $11.1M ($0.97/sh) in Q1 2024; R&D expenses rose to $9.1M from $7.7M, G&A to $5.0M from $4.1M.

## SEC filing metadata
- accession: 0001213900-25-040809
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390025040809/0001213900-25-040809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390025040809/ea0240929-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-040809
- JSON: https://secwatch.observer/filing/0001213900-25-040809.json
- Plain text: https://secwatch.observer/filing/0001213900-25-040809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.